ArticleLeukemia2019
ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis.
Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.Leukemia · 2026Review
- Genomic insights transform diagnosis, prognosis, and therapy in BCR::ABL1-negative myeloproliferative neoplasms.International journal of hematology · 2026Review
- The Role and Impact of Non-driver Gene Mutations in Myelofibrosis.Current hematologic malignancy reports · 2026Review
- The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN.Leukemia · 2025Article
- Pathogenesis and management of high molecular risk myeloproliferative neoplasms.Haematologica · 2025Review
- SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.Blood cancer journal · 2023Article
- JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.Journal of cancer research and clinical oncology · 2023Article
- Epigenetic regulation by ASXL1 in myeloid malignancies.International journal of hematology · 2023Review
- SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.Leukemia · 2023Article
- Article
- Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2Investigational new drugs · 2022Article
- ASXL1/2 mutations and myeloid malignancies.Journal of hematology & oncology · 2022Review
- Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720-2A>G variant.Journal of clinical laboratory analysis · 2022Article
- Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis.Leukemia · 2022Article
- Ruxolitinib Reduces Oxidative Stress in Patients With Primary Myelofibrosis: A Multicenter Study.Cureus · 2022Article
- Epigenetic Dysregulation of Myeloproliferative Neoplasms.Hematology/oncology clinics of North America · 2021Review
- Murine Models of Myelofibrosis.Cancers · 2020Review
- The Molecular Genetics of Myeloproliferative Neoplasms.Cold Spring Harbor perspectives in medicine · 2020Review
- The role of driver mutations in myeloproliferative neoplasms: insights from mouse models.International journal of hematology · 2020Review
- Accelerated Phase of Myeloproliferative Neoplasms.Acta haematologicaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30651633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.